Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s Sunosi®, Auvelity®, and Symbravo® products and the success of the ...

The company currently markets Auvelity (AXS-05) for treating major depressive disorder (MDD) and Sunosi (solriamfetol) for treating narcolepsy. Auvelity was launched in the United States in 2022 ...

It’s not known whether Sunosi (solriamfetol) is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine ...

Similarly, Sunosi's net revenue is projected to be nearly $25.7 million for the fourth quarter and $93.8 million for the full year, up from $74.8 million in 2023. The analysts expressed confidence ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...